Anthony J. Bolton
Direktor/Vorstandsmitglied bei FIL Ltd.
Profil
Anthony J.
Bolton is currently a Non-Executive Director at FIL Ltd.
and a Director at Immodulon Therapeutics Ltd.
He previously worked as the President of Investments at FIL Investment Advisors (UK) Ltd.
from 2009 to 2010 and as a Portfolio Manager at FIL Investment Management (Hong Kong) Ltd.
from 2010 to 2014.
Aktive Positionen von Anthony J. Bolton
Unternehmen | Position | Beginn |
---|---|---|
FIL Ltd.
FIL Ltd. Investment ManagersFinance FIL Ltd. provides investment advisory and financial management services. It offers class investment solutions and retirement expertise to institutions, individuals and advisers. The firm serves retail clients and intermediaries such as banks, financial advisers, and insurance companies. The company was founded by Edward C. Johnson III in 1969 and is headquartered in Pembroke, Bermuda.. | Direktor/Vorstandsmitglied | - |
Immodulon Therapeutics Ltd.
Immodulon Therapeutics Ltd. BiotechnologyHealth Technology Part of Lifexx SA, Immodulon Therapeutics Ltd. is a late-stage clinical biotechnology company based in Uxbridge, UK. Immodulon is developing a highly differentiated cancer immunotherapy approach that primes the patient’s own innate immune system with the aim to significantly enhance the efficacy of a broad range of anti-cancer therapies, including chemotherapy and checkpoint inhibitors. The British company is developing imm-101, a heat-killed mycobacterium obuense, as a broad-spectrum immunomodulatory agent with the potential to treat a range of difficult-to-treat tumors including those considered to be immunologically “ cold, ” such as pancreatic cancer. Immodulon's imm-101 based immunotherapy complements other cancer therapies, including immune checkpoint inhibitors and chemotherapy. The company is focused on developing safe and effective immunotherapy treatments. The company was founded in 2007 by Charles Akle, John L. Stanford. Gertjan Bartlema has been the CEO of the company since 2022. | Direktor/Vorstandsmitglied | 01.01.2015 |
Ehemalige bekannte Positionen von Anthony J. Bolton
Unternehmen | Position | Ende |
---|---|---|
FIL Investment Management (Hong Kong) Ltd.
FIL Investment Management (Hong Kong) Ltd. Investment ManagersFinance FIL Investment Management (Hong Kong) Ltd. (FIL-HK) is the wholly-owned, Hong Kong-based investment management subsidiary of FIL Ltd., a privately-owned group headquartered in Bermuda. The firm was founded in 1981 and formerly known as Fidelity Investments Management (Hong Kong) Ltd. FIL-HK offers several mutual funds to investors through over 100 distributors in Hong Kong, which includes retail banks and insurance companies. | Portfolio Manager-Aktien | 01.04.2014 |
FIL Investment Advisors (UK) Ltd.
FIL Investment Advisors (UK) Ltd. Investment ManagersFinance FIL Investment Advisors (UK) Ltd. (FIA UK) is a Great Britain-based fund management firm headquartered in Tadworth, Surrey. Founded in 1984, the firm is a wholly-owned subsidiary of FIL Holdings (UK) Limited, which in turn is a wholly-owned subsidiary of FIL Ltd. in Bermuda. FIA UK provides a range of global investment products and services to institutional accounts, mutual funds and other pooled investment vehicles. | Portfolio Manager-Aktien | 25.08.2009 |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
Private Unternehmen | 4 |
---|---|
FIL Investment Advisors (UK) Ltd.
FIL Investment Advisors (UK) Ltd. Investment ManagersFinance FIL Investment Advisors (UK) Ltd. (FIA UK) is a Great Britain-based fund management firm headquartered in Tadworth, Surrey. Founded in 1984, the firm is a wholly-owned subsidiary of FIL Holdings (UK) Limited, which in turn is a wholly-owned subsidiary of FIL Ltd. in Bermuda. FIA UK provides a range of global investment products and services to institutional accounts, mutual funds and other pooled investment vehicles. | Finance |
FIL Investment Management (Hong Kong) Ltd.
FIL Investment Management (Hong Kong) Ltd. Investment ManagersFinance FIL Investment Management (Hong Kong) Ltd. (FIL-HK) is the wholly-owned, Hong Kong-based investment management subsidiary of FIL Ltd., a privately-owned group headquartered in Bermuda. The firm was founded in 1981 and formerly known as Fidelity Investments Management (Hong Kong) Ltd. FIL-HK offers several mutual funds to investors through over 100 distributors in Hong Kong, which includes retail banks and insurance companies. | Finance |
FIL Ltd.
FIL Ltd. Investment ManagersFinance FIL Ltd. provides investment advisory and financial management services. It offers class investment solutions and retirement expertise to institutions, individuals and advisers. The firm serves retail clients and intermediaries such as banks, financial advisers, and insurance companies. The company was founded by Edward C. Johnson III in 1969 and is headquartered in Pembroke, Bermuda.. | Finance |
Immodulon Therapeutics Ltd.
Immodulon Therapeutics Ltd. BiotechnologyHealth Technology Part of Lifexx SA, Immodulon Therapeutics Ltd. is a late-stage clinical biotechnology company based in Uxbridge, UK. Immodulon is developing a highly differentiated cancer immunotherapy approach that primes the patient’s own innate immune system with the aim to significantly enhance the efficacy of a broad range of anti-cancer therapies, including chemotherapy and checkpoint inhibitors. The British company is developing imm-101, a heat-killed mycobacterium obuense, as a broad-spectrum immunomodulatory agent with the potential to treat a range of difficult-to-treat tumors including those considered to be immunologically “ cold, ” such as pancreatic cancer. Immodulon's imm-101 based immunotherapy complements other cancer therapies, including immune checkpoint inhibitors and chemotherapy. The company is focused on developing safe and effective immunotherapy treatments. The company was founded in 2007 by Charles Akle, John L. Stanford. Gertjan Bartlema has been the CEO of the company since 2022. | Health Technology |